Sarepta Therapeutics sells 9.3M Arrowhead shares for $174M and fulfills a $100M milestone payment. Read more here.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

The Japanese rhinoceros beetle, Trypoxylus dichotomus, is a large insect native to Asia, characterized by the large horn of ...

Arrowhead Pharmaceuticals (ARWR) announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Key Points Revenue (GAAP) increased 91.3% year-over-year to $15.3 million, compared to $8.0 million in Q2 2024, beating the consensus estimate by $1.2 million (GAAP). Net loss per share (GAAP) ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

The health secretary, who is a known vaccine skeptic, claimed that mRNA vaccines “fail to protect effectively against upper ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

This research demonstrates that gene editing can help crops better meet global food needs while adhering to environmental ...